Laurus Labs Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Laurus Labs Ltd. on BSE

Load latest

Laurus Labs Ltd.

09 Jan 2019

595.25

0.30%

Corp. Note

Laurus Labs Ltd - 540222 - Statement Of Investor Complaints For The Quarter Ended December 2018

BSE India

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- G. Venkateswar ReddyDesignation :- Company Secretary and Compliance Officer

Laurus Labs Ltd.

07 Jan 2019

595.25

0.30%

Corp. Note

Laurus Labs Ltd - 540222 - Shareholding for the Period Ended December 31, 2018

BSE India

Laurus Labs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2018. For more details, kindly Click here

Laurus Labs Ltd.

20 Dec 2018

595.25

0.30%

Corp. Note

Laurus Labs Ltd - 540222 - Laurus Labs Intimation Of Grant Of 537150 Stock Options

BSE India

In terms of the applicable provisions of SEBI (LODR) Regulations, 2015, we wish to inform you that, under Laurus Employees Stock Option Scheme - 2016 which is framed in accordance SEBI (SBEB) Regulations, 2014, the Nomination and Remuneration Committee of the Company has today granted 5,37,150 stock options of the face value of Rs.10/- ('options') each at the grant price of Rs. 292/- (Rupees Two hundred and ninety-two only) (i.e. 25% less than the Market Value of the Share on 19th December 2018) to 1,302 eligible employees of the Company. The effective date of Grant is 1st December, 2018.

pdf

Laurus Labs Ltd.

02 Dec 2018

595.25

0.30%

Company Update

Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Laurus Labs Limited ("the Company") is pleased to announce that the Company and Aspen Pharmacare, South Africa have launched a new HIV drug with the triple combination of Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate (DLT) in South Africa on 26 November 2018. A Press Release to this extent is also attached for your information and records.

pdf

Laurus Labs Ltd.

01 Dec 2018

595.25

0.30%

Company Update

Announcement under Regulation 30 (LODR)-Change in RTA

BSE India

The Company has been informed that pursuant to Order of the Hyderabad Bench of the National Company Law Tribunal (NCLT Order), the operations of Karvy Computershare Private Limited, the Share Transfer Agents of the Company (KCPL) have been transferred to Karvy Fintech Private Limited (Karvy Fintech) with effect from 17th November, 2018. The Company has been further informed that pursuant to the NCLT Order the all the existing agreements...

pdf

Laurus Labs Ltd.

12 Nov 2018, 01:28PM

595.25

0.30%

Earnings Call

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

Please refer to our intimation letter dated October 29, 2018 wherein we have intimated the schedule of Investor/Analyst call on November 02, 2018. In this connection please find attached transcription of conference call.

pdf

Laurus Labs Ltd.

10 Nov 2018

595.25

0.30%

SAST

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Naga Rani Chava

pdf

Laurus Labs Ltd.

10 Nov 2018

595.25

0.30%

SAST

Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Satyanarayana Chava

pdf

Laurus Labs Ltd.

02 Nov 2018

595.25

0.30%

Company Update

Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Laurus Labs Ltd ('the Company') is pleased to announce that the Company successfully completed the USFDA inspection of its Unit 6 API Intermediate Facility with one observation which is related to a procedure, on November 02, 2018. The manufacturing facility Unit 6 is located at Atchutapuram in Visakhapatnam, Andhra Pradesh and has 42 reactors with 253 Kilo liters capacity. A press release to this extent is also attached for your information and records.

pdf

Laurus Labs Ltd.

01 Nov 2018

595.25

0.30%

Investor Presentation

Laurus Labs Investor Presentation

BSE India

Please refer to our letter dated October 29, 2018, wherein we have intimated the schedule of Investors/Analysts call to be held on November 2, 2018. In this connection, we enclose herewith the presentation to the Investors/Analysts on the Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2018. The presentation is also being uploaded on the website of the Company - www.lauruslabs.com. Please take the information on record.

pdf

Is Laurus Labs Ltd. worth buying?

1218 Votes:

Buy 79.56%

Sell 10.84%

Hold 9.61%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf